Clinical Application of 89Zr-s-C1 PET/CT Imaging in Solid Tumors
ConditionSolid Tumors
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age15-70
SponsorPeking University Cancer Hospital & Institute
About this trial
This project is driven by clinical needs and focuses on the mucin (MUC) family, key glycopeptide antigens involved in mediating immune evasion in solid tumors. We selected multiple members of this family as research subjects. Based on the MUC18 target, we developed the probe ⁸⁹Zr-SS-CNB001 (HuAA98-14, hereafter referred to as ⁸⁹Zr-s-C1). Studies have demonstrated that ⁸⁹Zr-s-C1 PET/CT enables noninvasive in vivo identification of tumor lesions in patients with solid tumors, and its imaging efficacy positively correlates with MUC18 expression levels in the patient's tumor tissue.
Eligibility criteria
Qualifiers
Expected survival ≥ 12 weeks.
Good compliance with follow-up.
Presence of at least one measurable target lesion according to RECIST 1.1 criteria.
Female subjects must use effective contraception (effective contraception refers to sterilization, intrauterine hormone devices, condoms, contraceptive pills/agents, abstinence, or vasectomized partner) during the study and for 6 months after the study ends; male subjects must agree to use contraception during the study and for 6 months after the study ends.
Disqualifiers
Severe liver and kidney dysfunction.
Women preparing for pregnancy, pregnant, or breastfeeding.
Inability to lie flat for half an hour.
Inability to provide informed consent.
Trial design
Treatments tested in this trial
- Not listed
Trial groups
20 Participants
are grouped into 1 trial groupSponsors and collaborators
Source ClinicalTrials.gov